🚨 Spotlight on Targeted Therapy in Advanced NSCLC II & Rare Thoracic Malignancies at #ALCS2026! 🚨 From HER2 to ROS1 to brain metastases, Plenary 4 goes deep on the drivers and rare cases shaping the next frontier of lung cancer care. Here’s a sneak peek at the key topics we'll unpack: ✳️ HER2-Mutated NSCLC: New First-Line Therapy and Other Options ✳️ Targeting ALK and Managing Resistance ✳️ ROS1 Fusion: Novel Agents and New Insights ✳️ Beyond the Big Drivers: Targeting RET, MET, and BRAF ✳️ Brain Metastases in NSCLC: Rethinking Management in the Targeted Therapy Era Register today: loom.ly/lVR_I5k #LungCancer #LCSM #OncologyEducation #NSCLC #TargetedTherapy #RareCancers

20 years. One room. The best minds in lung cancer care. #ALCS2026 returns November 7 in Atlanta, GA—don’t miss the milestone. ✅ NSCLC & SCLC updates ✅ Targeted therapy & immunotherapy ✅ Expert debates & case discussions ✅ Peer networking 📅 Register: loom.ly/lVR_I5k #LungCancer #LCSM #OncologyEducation

🚨 Spotlight on Targeted Therapy in Advanced NSCLC at #ALCS2026! 🚨 The targeted therapy landscape is moving fast, and Plenary 3 is where we break it all down. Here’s a sneak peek at the key topics we’ll unpack: ✳️ EGFR-Mutated NSCLC: Common and Exon 20 Insertion Mutations ✳️ KRAS-Mutated NSCLC: The Next Targeted Therapy Frontier ✳️ Are ADCs Truly Transformational in NSCLC? Expert Debate Register today: loom.ly/lVR_I5k #LungCancer #LCSM #OncologyEducation #NSCLC #TargetedTherapy

One month until #ALCS2026 — November 7th in Atlanta, GA. ⏳ 🔹 NSCLC advances 🔹 Targeted therapy & immunotherapy updates 🔹 SCLC management 🔹 Multidisciplinary case discussions Secure your spot now: loom.ly/lVR_I5k #LungCancer #LCSM #NSCLC

Nearly 230,000 Americans will be diagnosed with lung cancer in 2026, accounting for 1 in 5 of all cancer deaths. (ACS, Cancer Facts & Figures 2026) This November 7th, the experts driving the field forward will be in 1 room at #ALCS2026. 📅 Register: loom.ly/lVR_I5k #LungCancer #LCSM #OncologyEducation

🚨 Spotlight on Advanced NSCLC & SCLC at #ALCS2026! 🚨 Join us for an in-depth Plenary Session exploring the latest in advanced lung cancer management, where the science is evolving and the debates are heating up. Here’s a sneak peek at the key topics we’ll unpack: ✳️ Immunotherapy for Advanced NSCLC: New Agents and Novel Combinations ✳️ Small Cell Lung Cancer: Expanding Options, More Hope ✳️ Locally Advanced NSCLC: Have We Hit the Ceiling? ✳️ MRD Status Should Guide Adjuvant Therapy — Expert Debate Register today: loom.ly/lVR_I5k #LungCancer #LCSM #OncologyEducation #NSCLC #SCLC

The field is moving fast. Stay ahead of it. Join us at the 20th Annual #ALCS2026 — November 7th in Atlanta, GA. 🔹 NSCLC advances 🔹 Targeted therapy & immunotherapy updates 🔹 SCLC management 🔹 Multidisciplinary case discussions 📅 Register: loom.ly/lVR_I5k #LungCancer #LCSM #NSCLC #CME

🚨 Spotlight on Early-Stage and Locally Advanced #NSCLC at #ALCS2026! 🚨 Join us for an insightful Plenary Session diving deep into the multidisciplinary integration of neoadjuvant, surgical, and adjuvant therapies for early-stage and locally advanced NSCLC. Here’s a sneak peek at the key topics we’ll unpack: ✳️ Advances in Targeted Therapies: EGFR, ALK, and RET-Positive NSCLC ✳️ Neoadjuvant vs Adjuvant Therapy: Is the Debate Over? ✳️ What Is Resectable Lung Cancer Today? ✳️ Practical Applications of Advanced Diagnostic Approaches in Lung Cancer ✳️ Multidisciplinary Team (MDT) Case Panel Discussion Register today: loom.ly/lVR_I5k #LungCancer #LCSM #Oncology

Thank you for joining us at #iwNHL26. The conversations continue — save the date for the next International Workshop on Non-Hodgkin Lymphoma, October 22-24, 2027 - Location coming soon!. We look forward to welcoming the global lymphoma community again. #iwNHL #Lymphoma

As #iwNHL26 closes, co-chairs John Gribben of @NHSBartsHealth and @DrJasonWestin of @UTMDAnderson reflect on 2 days of discussion, debate, and collaboration focused on improving outcomes for patients with NHL. Thank you to the faculty, attendees, and supporters! #Lymphoma

Rapid-fire perspectives at #iwNHL26 cover BsAbs in community practice, outpatient CAR T-cell therapy, digital pathology, and AI in radiology, with experts from @PennMedicine and @Stanford. Which innovation will have the biggest impact on NHL care? #Lymphoma #DigitalPathology

Can MRD testing become routine in NHL? Mark Hamilton of @UTMDAnderson and session chair Mark Roschewski of @sloan_kettering discuss practical challenges, unanswered questions, and opportunities as MRD technologies evolve. #iwNHL26 #MRD #Lymphoma #Biomarkers

How do we expand access to CAR T-cell therapy? Tanya Siddiqi, @LNastoupilMD, Lorna Warwick, and Miguel Perales of @sloan_kettering share academic, community, and patient advocacy perspectives on overcoming barriers. #iwNHL26 #CARTcell #CellTherapy #PatientAccess

AI is coming to lymphoma care. Swaminathan Iyer of @UTMDAnderson and session chair Steven Rosen explore how artificial intelligence may influence lymphoma research, diagnostics, clinical decision-making, and future care delivery. #iwNHL26 #ArtificialIntelligence #DigitalHealth #Lymphoma

Day 2 begins at #iwNHL26 with a deep dive into bispecific and trispecific antibodies in NHL, chaired by Martin Hutchings and Marion Subklewe. Faculty will examine leading agents and emerging combinations across earlier lines of treatment. #BispecificAntibodies #TrispecificAntibodies #Lymphoma

Rapid-fire perspectives at #iwNHL26 cover BsAbs in community practice, outpatient CAR T-cell therapy, digital pathology, and AI in radiology, with experts from @PennMedicine and @Stanford. Which innovation will have the biggest impact on NHL care? #Lymphoma #DigitalPathology #CARTcell #AI